By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Lysosomal enzymes > Vestronidase alfa > Vestronidase Alfa Dosage
Lysosomal enzymes
https://themeditary.com/dosage-information/vestronidase-alfa-dosage-9747.html

Vestronidase Alfa Dosage

Drug Detail:Vestronidase alfa (Vestronidase alfa [ ves-tron-i-dase-al-fa ])

Drug Class: Lysosomal enzymes

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Mucopolysaccharidosis Type VII

4 mg/kg IV infusion once every 2 weeks

Use: For the treatment of Mucopolysaccharidosis VII (MPS VII) also known as Sly syndrome

Usual Pediatric Dose for Mucopolysaccharidosis Type VII

4 mg/kg IV infusion once every 2 weeks

Use: For the treatment of Mucopolysaccharidosis VII (MPS VII) also known as Sly syndrome

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING:

  • ANAPHYLAXIS: Anaphylaxis has occurred with administration of this drug, as early as the first dose, therefore, appropriate medical support should be readily available when this drug is administered. Closely observe patients during and for 60 minutes after infusion. Immediately discontinue the infusion if the patient experiences anaphylaxis.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • For IV infusion only.
  • Administer the diluted solution using a low protein binding infusion set with an in-line, low protein binding 0.2 micron filter.
  • This drug should be administered under the supervision of a healthcare professional with the ability to manage anaphylaxis.
  • Premedication is recommended 30 to 60 minutes prior to the start of the infusion, including a nonsedating antihistamine with or without an antipyretic.
  • Administer infusion over about 4 hours; infuse the first 2.5% of the total volume over the first hour; after the first hour, increase the infusion rate as tolerated in order to complete infusion over the following 3 hours according to the recommended rate guidelines.
  • Observe patients closely during infusion and for at least 60 minutes after the infusion for the development of anaphylaxis.
  • Discontinue infusion immediately if severe systemic reaction, including anaphylaxis, occurs.
  • The manufacturer product information should be consulted for further information, including rate of infusion.

Storage requirements:
  • Store vials at 2C to 8C (36F to 46F); do not freeze or shake; protect from light.
  • Diluted solution: If not used immediately, diluted solution may be stored up to 36 hours at 2C to 8C (36F to 46F) followed by up to 6 hours at room temperature up to a maximum of 25C (77F).
  • Any unused product should be discarded.

Reconstitution/preparation techniques:
  • The manufacturer product information should be consulted.

IV compatibility:
  • Do not infuse with other products in the infusion tubing.
  • Do not flush the line containing this drug to avoid a rapid bolus of infused enzyme; due to the low infusion rate, additional saline may be added through a separate line (piggyback or Y tube) to maintain sufficient intravenous flow to prevent clotting or line blockage.

General:
  • The effect of this drug on the central nervous system manifestations of MPS VII has not been established.

Monitoring:
  • Immunologic: Observe patients during and for at least 60 minutes after infusion for severe reactions, including anaphylaxis.

Patient advice:
  • Seek immediate medical care if signs/symptoms of anaphylaxis occur.
Share this Article
Latest News
Medical News

Type 2 diabetes: Sugary drinks may significantly raise risk

May 30, 2025
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Ministrokes may result in 1 year of chronic fatigue
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by